Background. Characteristics, associated factors, and survival probability of toxoplasmic encephalitis (TE) in the era of advanced highly active antiretroviral therapy ( HAART) have not been fully clarified. Methods. Data for 205 individuals with acquired immunodeficiency syndrome ( AIDS)-related TE were derived from the Italian Registry Investigative NeuroAIDS database, and the cases were studied longitudinally to evaluate prevalence, clinical characteristics, and survival. Moreover, the relationship between the occurrence of TE and exposure to antiretroviral therapy and to TE prophylaxis was evaluated. Results. With an overall prevalence of 26%, TE represented the most frequent neurological disorder in the cohort. Female sex, severe immunodeficiency, and absence of primary TE prophylaxis significantly increased the risk of TE, and previous exposure to antiretroviral therapy reduced the probability of disease occurrence. Thirty-six percent of patients who had received antiretroviral therapy developed TE, although in most of these cases, the patient experienced failure of antiretroviral therapy. Of note, 66% of patients who had experienced antiretroviral therapy did not receive prophylaxis for TE at TE diagnosis. The 1-year probability of that infection with human immunodeficiency virus (HIV) would progress or that death would occur after TE was 40% and 23%, respectively. Cognitive symptoms, low CD4(+) cell count, not receiving HAART after TE, and initiating HAART 12 months after TE diagnosis were all significantly associated with an increased probability of progression of HIV infection. Not receiving HAART after diagnosis negatively affected survival. Conclusions. TE remains a highly prevalent disorder of the central nervous system, even in the late HAART era, particularly among severely immunosuppressed patients and in absence of prophylaxis. Considering that persons with TE have a high probability of early death, prophylaxis should be maintained in immunosuppressed patients who experience failure of antiretroviral therapy, and HAART should be initiated as soon as possible after TE diagnosis.

Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy / A., Antinori; D., Larussa; A., Cingolani; P., Lorenzini; S., Bossolasco; M. G., Finazzi; M., Bongiovanni; Guaraldi, Giovanni; S., Grisetti; B., Vigo; B., Gigli; A., Mariano; E. R., Dalle Nogare; M., De Marco; F., Moretti; P., Corsi; N., Abrescia; P., Rellecati; A., Castagna; Mussini, Cristina; A., Ammassari; P., Cinque; A., D' Arminio Monforte; Cingolani, A; Italian Registry Investigative, Neuroaids. - In: CLINICAL INFECTIOUS DISEASES. - ISSN 1058-4838. - STAMPA. - 39 (11):(2004), pp. 1681-1691. [10.1086/424877]

Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy

GUARALDI, Giovanni;MUSSINI, Cristina;
2004

Abstract

Background. Characteristics, associated factors, and survival probability of toxoplasmic encephalitis (TE) in the era of advanced highly active antiretroviral therapy ( HAART) have not been fully clarified. Methods. Data for 205 individuals with acquired immunodeficiency syndrome ( AIDS)-related TE were derived from the Italian Registry Investigative NeuroAIDS database, and the cases were studied longitudinally to evaluate prevalence, clinical characteristics, and survival. Moreover, the relationship between the occurrence of TE and exposure to antiretroviral therapy and to TE prophylaxis was evaluated. Results. With an overall prevalence of 26%, TE represented the most frequent neurological disorder in the cohort. Female sex, severe immunodeficiency, and absence of primary TE prophylaxis significantly increased the risk of TE, and previous exposure to antiretroviral therapy reduced the probability of disease occurrence. Thirty-six percent of patients who had received antiretroviral therapy developed TE, although in most of these cases, the patient experienced failure of antiretroviral therapy. Of note, 66% of patients who had experienced antiretroviral therapy did not receive prophylaxis for TE at TE diagnosis. The 1-year probability of that infection with human immunodeficiency virus (HIV) would progress or that death would occur after TE was 40% and 23%, respectively. Cognitive symptoms, low CD4(+) cell count, not receiving HAART after TE, and initiating HAART 12 months after TE diagnosis were all significantly associated with an increased probability of progression of HIV infection. Not receiving HAART after diagnosis negatively affected survival. Conclusions. TE remains a highly prevalent disorder of the central nervous system, even in the late HAART era, particularly among severely immunosuppressed patients and in absence of prophylaxis. Considering that persons with TE have a high probability of early death, prophylaxis should be maintained in immunosuppressed patients who experience failure of antiretroviral therapy, and HAART should be initiated as soon as possible after TE diagnosis.
39 (11)
1681
1691
Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy / A., Antinori; D., Larussa; A., Cingolani; P., Lorenzini; S., Bossolasco; M. G., Finazzi; M., Bongiovanni; Guaraldi, Giovanni; S., Grisetti; B., Vigo; B., Gigli; A., Mariano; E. R., Dalle Nogare; M., De Marco; F., Moretti; P., Corsi; N., Abrescia; P., Rellecati; A., Castagna; Mussini, Cristina; A., Ammassari; P., Cinque; A., D' Arminio Monforte; Cingolani, A; Italian Registry Investigative, Neuroaids. - In: CLINICAL INFECTIOUS DISEASES. - ISSN 1058-4838. - STAMPA. - 39 (11):(2004), pp. 1681-1691. [10.1086/424877]
A., Antinori; D., Larussa; A., Cingolani; P., Lorenzini; S., Bossolasco; M. G., Finazzi; M., Bongiovanni; Guaraldi, Giovanni; S., Grisetti; B., Vigo; B., Gigli; A., Mariano; E. R., Dalle Nogare; M., De Marco; F., Moretti; P., Corsi; N., Abrescia; P., Rellecati; A., Castagna; Mussini, Cristina; A., Ammassari; P., Cinque; A., D' Arminio Monforte; Cingolani, A; Italian Registry Investigative, Neuroaids
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/307826
Citazioni
  • ???jsp.display-item.citation.pmc??? 33
  • Scopus 120
  • ???jsp.display-item.citation.isi??? 88
social impact